Current SATVI news
Professor Tom Scriba and Dr Simon Mendelsohn have published a journal article titled: "Making headway towards biosgnatures for incipient tuberculosis" appearing in the Lancet Respiratory Medicine.
The Prevention of Recurrence (POR) Consortium has been awarded a substantial grant from the European & Developing Countries Clinical Trial Partnership (EDCTP) which will support a clinical trial in South Africa and Tanzania of a new and promising tuberculosis (TB) vaccine candidate H56:IC31, developed by the Statens Serum Institute (SSI).
Professor Mark Hatherill has co-authored a journal article titled: "Preferred product characteristics for therapeutic vaccines to improve tuberculosis treatment outcomes: Key considerations from World Health Organisation consultations" appearing in the Vaccine journal.
Dr Michèle Tameris, has co-authored a book chapter titled "Between representing and intervening: Diagnosing childhood tuberculosis during a vaccine trial in South Africa".
Dr Angelique Luabeya has been awarded "C" rating from the National Research Foundation.
The interim Dean of the UCT Faculty of Health Sciences has just announced that SATVI Senior Research Officer, Elisa Nemes has been promoted to Associate Professor.
TB Science Official Press Conference: Watch announcement of final results from M72/AS01E candidate vaccine against tuberculosis (TB) online.
Press Conference: Towards a TB Vaccine, Union World Conference, 29 October 2019: Watch press conference where the final results M72/AS01E candidate vaccine against tuberculosis (TB) were announced at the Union Conference on Lung Health, India.
Results from the MM72/AS01E TB vaccine study have been presented at the Union Conference on Lung Health, India.
SATVI is calling for applicants to the position of Laboratory Technologist at its Worcester field site. NOW CLOSED.
SATVI researchers Professors Mark Hatherill, Tom Scriba, Dr Bilek, Darboe, Mbandi, Penn-Nicholson have co-authored a research article titled "Plasma Type I IFN Protein Concentrations in Human Tuberculosis." appearing in the Frontiers in Cellular and Infection Microbiology.
Professor Mark Hatherill has co-authored a journal article titled "FDG-PET/CT as a non-invasive biomarker for assessing adequacy of treatment and predicting relapse in patients treated for pulmonary tuberculosis" appearing in the Journal of Nuclear Medicine.